71.4 F
New York
Friday, October 15, 2021

Novartis [NYSE: NVS] Announces Acquisition of Arctos Medical

Must read

Turquoise Hill [NYSE: TRQ] Shares Oyu Tolgoi Mine Update

Turquoise Hill Resources Ltd. disclosed Q3 2021 production for Oyu Tolgoi LLC (Oyu Tolgoi) and shared an update on the Oyu Tolgoi mine....

Amazon’s [NASDAQ: AMZN] AWS Chosen by NXP as Preferred Cloud Provider

Amazon.com, Inc. disclosed that NXP Semiconductor has chosen AWS as its preferred cloud provider. NXP has decided to shift the broad majority of...

Accenture [NYSE: ACN] Announces Acquisition of BRIDGEi2i

Accenture plc disclosed that it has inked an agreement to purchase BRIDGEi2i which is an artificial intelligence (AI) and analytics firm based in...

Rio Tinto’s [NYSE: RIO] Perth Airport Vaccination Clinics Begins for Mining Industry

Rio Tinto Group has disclosed that its vaccination hub at Perth Airport has started COVID-19 vaccination for the workers of the mining industry. ...

Novartis AG [NYSE: NVS] disclosed that it has acquired Arctos Medical. This purchase decision will add a pre-clinical optogenetics-based AAV gene therapy program and Arctos’ proprietary technology to its ophthalmology portfolio. Optogenetics is a promising therapeutic approach that is evolving nowadays and is likely to help sufferers who are legally blind regain sight.

The purchase of Arctos highlighted the Novartis commitment to exploring cures for sufferers experiencing vision loss and the capability of optogenetics as the basis of successful therapeutics. Arctos designed its technology as a possible method for curing inherited retinal dystrophies (IRDs) and other diseases that include photoreceptor loss, such as age-related macular degeneration (AMD).

Furthermore, NVS disclosed the reason to acquire Arctos Medical. The firm believed that the Arctos technology was designed on its belief that optogenetic gene therapies may meaningfully aid patients struggling with destructive eye diseases. Arctos’ proprietary, light-sensitive optogene is given to specific retinal cells using gene therapy, thus changing the targeted cells into replacement photoreceptor-like cells.

Additionally, IRDs have currently affected more than 2 million people all around the globe. IRDs often caused complete blindness. It can be triggered by mutations in over 100 different genes. NVS believed that if this approach will be successful then this technology could be used to cure any disease that triggers blindness due to photoreceptor death.

More articles

Latest article

21Shares Lists 5 Additional Crypto ETPs on Euronext Paris and Amsterdam

21Shares which has earned a reputation as the world’s largest issuer of cryptocurrency ETPs has disclosed that it has listed 5 additional ETPs in...

Electronic Arts [NASDAQ: EA] Share its Clear Vision for the Future of Football

Electronic Arts Inc. has disclosed a record-breaking FIFA 22 launch and also shared its stance on the future of football. EA has talked...

Bitcoin, Ethereum Gain All-Time High as SEC Confirms no Plan To Ban Cryptocurrency

Bitcoin, Ethereum, Dogecoin traded all-time high after the U.S. SEC Chair Gary Gensler disclosed that HEC is not considering the China-like cryptocurrency ban policy...

KuCoin Cryptocurrency Exchange Decides Not to Offer Services to Mainland China Customer

Cryptocurrency exchange KuCoin has decided to respond to the crackdown of Chinese authorities. The firm has disclosed that the customer in Mainland China will...

Bitcoin Firm Bitfarms [NASDAQ: BITF] Decides to Expand Québec Mining Operations

Bitcoin mining Bitfarms Ltd. disclosed that it has decided to increase its corporate hash rate to more than 1.6 Exahash per second (EH/s)....

KKR [NYSE: KKR] Announces Acquisition of Probe CX

KKR & Co. Inc. disclosed that it has inked an acquisition agreement with Quadrant Private Equity, Five V Capital, Rodney Kagan, and other...

Regeneron’s [NASDAQ: REGN] REGEN-COV Shows Promising Results in Hospitalized COVID-19 Patients

Regeneron Pharmaceuticals, Inc. disclosed that REGEN-COV which is the combination of casirivimab and imdevimab has demonstrated promising results in hospitalized COVID-19 sufferers. These...

Huntsman [NYSE: HUN] and KPX Chemical Establish Joint Venture in Korea

Huntsman Corporation has disclosed that it has joined forces with KPX Chemical to launch a joint venture (JV) in Korea. The joint venture...